Product Pipeline

IND Code Dosage Form Features Indications Development Development
Locations Stage
TAS-102 Oral Interference with the function of DNA Colorectal cancer Asia Filed
Gastric cancer Japan Filed
EU Filed
TAS-118 Oral Anti-metabolite Gastric cancer Japan Phase III
Asia Phase III
TAS-114 Oral dUTPase inhibitor Non-small cell lung cancer (NSCLC) Japan Phase II
US Phase II
EU Phase II
TAS-115 Oral Multi-kinase inhibitor Prostate cancer Japan Phase II
Idiopathic pulmonary fibrosis Japan Phase II
TAS-116 Oral HSP90 inhibitor Gastrointestinal stromal tumor (GIST) Japan Phase III
Solid tumors US Phase I
EU Phase I
TAS-117 Oral 　 Solid tumors Japan Phase I
TAS-119 Oral 　 Solid tumors US Phase I
EU Phase I
TAS-120 Oral FGFR inhibitor Cholangiocarcinoma Japan Phase Ⅱ
US Phase Ⅱ
EU Phase Ⅱ
TAS0313 Injection 　 Urothelial cancer Japan Phase Ⅱ
TAS3681 Oral 　 Prostate cancer US Phase I
EU Phase I
TAS4464 Injection 　 Solid tumors, Hematological cancer Japan Phase I
US Phase I
EU Phase I
TAS0728 Oral 　 Solid tumors US Phase Ⅰ/Ⅱ
EU Phase Ⅰ/Ⅱ
ET-743 Injection 　 Ovarian cancer Japan Phase I
Pro-NETU Injection NK1 receptor antagonist Chemotherapy-induced nausea and vomiting (CINV) Japan Phase III
TAS-205 Oral PGD synthase inhibitor Duchenne muscular dystrophy(DMD) Japan Phase II
TAS5315 Oral BTK inhibitor Rheumatoid arthritis(RA) Japan Phase II
TAC-302 Oral 　 Detrusor underactivity with overactive bladder Japan Phase II
TAS-303 Oral Selective norepinephrine
reuptake inhibitor		 Stress urinary incontinence Japan Phase II

As of June 30, 2019

muscular